Litigation Details for Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd. (D. Del. 2020)

Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd. (D. Del. 2020)

Docket	1:20-cv-01426	Date Filed	2020-10-23
Court	District Court, D. Delaware	Date Terminated	2023-03-27
Cause		Assigned To	Gregory B. Williams
Jury Demand		Referred To
Patents	10,124,000; 7,314,938; 7,745,460; 7,790,743; 7,928,122; 8,084,047; 8,168,655; 8,367,701; 8,592,450; 8,927,574; 9,085,553; 9,216,174; 9,353,088; 9,447,077; 9,890,141
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-10-23				External link to document
2020-10-23	1	Complaint	,174 (“the ’174 patent”); U.S. Patent No. 10,124,000 (“the ’000 patent”); U.S. Patent No. 8,084,047 (…of U.S. Patent No. 7,314,938 (“the ’938 patent”); U.S. Patent No. 7,745,460 (“the ’460 patent”); U.S.…U.S. Patent No. 7,790,743 (“the ’743 patent”); U.S. Patent No. 7,928,122 (“the ’122 patent”); U.S. Patent… (“the ’047 patent”); U.S. Patent No. 8,592,450 (“the ’450 patent”); U.S. Patent No. …8,168,655 (“the ’655 patent”); U.S. Patent No. 8,367,701 (“the ’701 patent”); U.S. Patent No. 9,447,077 (	External link to document
2020-10-23	3	ANDA Form	November 5, 2024 10,124,000 November 5,… Date of Expiration of Patents: U.S. Patent No. …. SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG	External link to document

Novartis Pharmaceuticals v. Aurobindo Pharma, 1:20-cv-01426: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Novartis Pharmaceuticals sued Aurobindo Pharma under the Hatch-Waxman Act after Aurobindo filed an Abbreviated New Drug Application seeking approval for a generic version of Entresto, the sacubitril/valsartan heart-failure product. The case was filed in the U.S. District Court for the District of Delaware in 2020 and involved Orange Book-listed Entresto patents. The matter ended without a reported trial decision establishing the validity or infringement of the asserted patents. The dispute was resolved through a confidential settlement and dismissal.

What drug was targeted in Novartis v. Aurobindo?

The litigation concerned Entresto, a fixed-dose combination of sacubitril and valsartan.

Product	Active ingredients	FDA use	Reference sponsor
Entresto	Sacubitril/valsartan	Heart failure with reduced ejection fraction and related heart-failure indications	Novartis Pharmaceuticals
Proposed generic	Sacubitril/valsartan	Same or substantially overlapping indications	Aurobindo Pharma

Entresto combines sacubitril, a neprilysin inhibitor, with valsartan, an angiotensin II receptor blocker. The product is administered in multiple strengths, including 24/26 mg, 49/51 mg and 97/103 mg tablets.

Aurobindo’s ANDA filing triggered the litigation through Paragraph IV certifications challenging Novartis’s Orange Book patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or would not be infringed by the proposed generic product. Filing a Paragraph IV certification gives the brand company a statutory basis to sue for patent infringement before generic approval. [1]

When and where was the case filed?

Field	Information
Case	Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd.
Civil action	No. 1:20-cv-01426
Court	U.S. District Court for the District of Delaware
Filing year	2020
Nature of action	Hatch-Waxman patent infringement
Plaintiff	Novartis Pharmaceuticals Corporation
Defendants	Aurobindo Pharma entities
Product	Generic sacubitril/valsartan tablets
Procedural result	Settlement and dismissal
Published merits judgment	None reported

Novartis filed the action after receiving notice of Aurobindo’s Paragraph IV certifications. The complaint sought the standard Hatch-Waxman remedies, including a declaration of infringement and an injunction preventing FDA approval or commercial launch of Aurobindo’s ANDA product before the expiration of the asserted patents.

What patents protect Entresto in this litigation?

The Entresto patent estate has included patents directed to the active-ingredient combination, pharmaceutical compositions, dosage forms and methods of treatment. The patents potentially relevant to generic sacubitril/valsartan litigation include the following families:

Patent	General subject matter	Relevance to generic litigation
U.S. Patent No. 8,877,938	Sacubitril/valsartan combination and related pharmaceutical compositions	Core composition and product protection
U.S. Patent No. 9,388,134	Sacubitril/valsartan pharmaceutical composition	Formulation and composition protection
U.S. Patent No. 9,517,226	Sacubitril/valsartan treatment methods and related claims	Method-of-use protection
U.S. Patent No. 10,011,637	Later Entresto formulation or use claims	Potential follow-on protection
Other later-listed patents	Additional formulation, use or pediatric claims	Secondary launch barriers

The exact asserted patent set depends on the claims made in Novartis’s complaint and any amended pleadings. Orange Book listings can change during the life of an ANDA dispute as patents issue, are listed, expire or are delisted. The case should therefore be distinguished from the broader Entresto patent portfolio. [2]

What formulations were protected?

Entresto’s patent strategy included more than a simple active-ingredient claim. The relevant protection has covered:

• The combination of sacubitril and valsartan in a single dosage form.
• Pharmaceutical compositions containing the two active ingredients.
• Specific dose ratios and strengths.
• Tablet formulations and excipient systems.
• Methods of treating heart failure using the combination.
• Pediatric or expanded-indication use claims in later patent filings.

Formulation patents can create a separate entry barrier even after an earlier composition patent expires. Their commercial value depends on claim scope, Orange Book listing status, the generic’s proposed formulation and whether a design-around is technically and commercially practical.

What was Aurobindo’s Paragraph IV position?

Aurobindo’s ANDA certification placed the Entresto patents directly in dispute. The principal legal issues in this type of action are:

1. Whether Aurobindo’s proposed sacubitril/valsartan product would infringe the asserted claims.
2. Whether the asserted claims were anticipated or obvious.
3. Whether Novartis’s patent claims satisfied written-description and enablement requirements.
4. Whether the claims were enforceable.
5. Whether method-of-use claims could be enforced against the proposed labeling.
6. Whether Aurobindo could launch after expiration of the relevant patents or under a carved-out label.

Because the case ended in settlement, the court did not issue a reported opinion resolving those questions. The absence of a merits ruling means the proceeding did not create binding precedent on the validity or enforceability of the Entresto patents.

How did the litigation affect FDA approval?

A Hatch-Waxman patent suit filed within 45 days of a Paragraph IV notice generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii). The stay prevents FDA approval while the patent dispute proceeds, subject to statutory exceptions.

The stay is an approval barrier, not necessarily a permanent launch prohibition. It can end through:

• Patent expiration.
• A court decision favoring the ANDA applicant.
• Settlement terms allowing an agreed launch date.
• A court order lifting or shortening the stay.
• Failure of the brand company to satisfy statutory requirements.

The litigation therefore affected the timing of Aurobindo’s potential approval and launch, but the case itself did not produce a public judicial finding that Aurobindo’s product was infringing.

What was the settlement and generic launch outcome?

The parties resolved the dispute confidentially. The public disposition did not disclose the commercial terms, including:

• Any agreed generic launch date.
• Whether Aurobindo received a license.
• Whether the license covered all strengths or only selected strengths.
• Whether the settlement included supply, royalty or co-promotion provisions.
• Whether Aurobindo obtained an authorized-generic arrangement.
• Whether the agreement included acceleration rights tied to other generic entrants.

The dismissal means the case no longer presented an active judicial barrier between Novartis and Aurobindo. It does not, by itself, establish that Aurobindo was free to launch immediately. Launch rights depend on the settlement, FDA approval, applicable patent expiration dates and any other Entresto litigation involving Aurobindo or its affiliates.

When does Entresto lose exclusivity?

Entresto’s exclusivity has several separate components.

Exclusivity type	Relevance
New chemical entity exclusivity	Generally not the central remaining barrier for an older combination product
Patent exclusivity	Determined by each listed patent’s expiration date and any patent-term adjustment or pediatric extension
Regulatory exclusivity	May apply to particular indications or populations
ANDA litigation stay	Can delay approval for up to 30 months after a timely Paragraph IV suit
Settlement-based exclusivity	May establish a private launch date for a settling generic

The earliest relevant patent expiration does not automatically create unrestricted generic competition. A generic applicant must assess every Orange Book-listed patent, the scope of each claim and the risk that a later patent may support a separate infringement action.

For commercial forecasting, the key question is not simply when the earliest Entresto patent expires. The relevant date is the earliest date on which a commercially viable generic can obtain FDA approval and market the product without violating an enforceable patent or settlement restriction.

Does this case involve biosimilar risk?

No. Entresto is a small-molecule drug, not a biologic. Aurobindo’s application proceeded through the ANDA pathway, not the Biologics Price Competition and Innovation Act biosimilar pathway.

The competitive risks are therefore:

• Paragraph IV generic challenges.
• Abbreviated new drug applications.
• Potential first-filer exclusivity.
• Formulation design-arounds.
• Multiple-generic price erosion after approval.
• Settlement-controlled launch timing.

Biosimilar interchangeability, reference-product exclusivity and biologic licensing issues do not apply to this case.

How strong was Novartis’s patent estate?

The estate was commercially meaningful because it combined several layers of protection around a high-value cardiovascular product. Its strength can be assessed as follows:

Factor	Assessment
Product importance	High; Entresto was a major Novartis cardiovascular product
Core combination protection	Strong commercial value, subject to validity and claim-construction challenges
Formulation protection	Potentially important where the generic uses overlapping tablet technology
Method-of-use claims	Useful where the ANDA label includes the patented indication
Design-around potential	Moderate; sacubitril/valsartan products may be engineered around some formulation claims
Litigation leverage	High before patent expiry, particularly where multiple patents are listed
Litigation certainty	Limited because the Aurobindo case ended without a merits decision

The estate’s practical strength depended on claim breadth, prosecution history, prior art, FDA labeling and the proposed ANDA formulation. A settlement can indicate that both parties valued litigation risk, but it is not evidence that the patents would necessarily have survived a validity challenge.

Which companies challenged Entresto patents?

Entresto has been subject to broader generic competition involving multiple ANDA applicants. The relevant competitive group has included major generic manufacturers and their affiliates, including Aurobindo and other applicants pursuing sacubitril/valsartan products.

Each defendant’s settlement or judgment must be analyzed separately. A settlement with one generic company does not automatically authorize launch by another applicant. It also does not resolve validity issues for non-parties unless a later court ruling or agreement provides otherwise.

What patent litigation affects generic Entresto entry?

Generic entry depends on the combined effect of:

1. The Aurobindo settlement.
2. Other pending or resolved Entresto cases.
3. The Orange Book patent list at the time of FDA approval.
4. The ANDA applicant’s Paragraph IV certifications.
5. Any first-filer exclusivity.
6. The commercial scope of the settlement license.
7. Patent-term adjustments and pediatric extensions.
8. The generic’s formulation and labeling.

Aurobindo’s dismissal removed one contested case from the docket but did not eliminate the broader patent and regulatory analysis required for Entresto entry.

What was the revenue exposure for Novartis?

Entresto was a major growth product for Novartis, making generic entry strategically material. The financial impact of generic competition depends on:

• The first commercial launch date.
• The number of approved generic suppliers.
• Whether the first entrant has 180-day exclusivity.
• The degree of price discount.
• Payer substitution and formulary treatment.
• The speed of multi-source generic adoption.
• The share of Entresto prescriptions exposed to substitution.

A single authorized or licensed generic may produce a slower erosion curve than simultaneous independent generic entry. A broad generic launch can cause rapid net-price compression and prescription substitution, particularly in a mature chronic-use cardiovascular market.

Key Takeaways

• Novartis sued Aurobindo in Delaware over a Paragraph IV ANDA for generic sacubitril/valsartan, the active combination in Entresto.
• The case was a Hatch-Waxman patent dispute, not a biosimilar proceeding.
• The asserted technology was part of Novartis’s broader Entresto composition, formulation and method-of-use patent estate.
• The case ended through confidential settlement and dismissal.
• No reported merits decision determined whether the asserted patents were valid or infringed.
• The settlement removed the case as an active judicial dispute but did not publicly disclose Aurobindo’s launch date or licensing rights.
• Generic entry depends on the settlement, FDA approval, Orange Book patents, other Entresto litigation and any applicable exclusivity periods.
• The case remains commercially relevant because Entresto represents a significant Novartis revenue exposure to small-molecule generic erosion.

FAQs

Does dismissal mean Aurobindo could immediately launch generic Entresto?

No. Dismissal ends the court action, but launch rights depend on the confidential settlement, FDA approval and any surviving patent restrictions.

Was Novartis v. Aurobindo a patent-validity decision?

No reported merits decision resolved the validity, enforceability or infringement of the Entresto patents in this action.

Is sacubitril/valsartan protected by formulation patents?

Yes. Novartis’s Entresto estate has included composition, formulation, dosage and method-of-use claims. The enforceability of any particular claim depends on the patent and the generic’s proposed product.

Does Entresto have biosimilar competition?

No. Entresto is a small-molecule combination product. Competition proceeds through ANDAs and generic-drug litigation.

Can another generic company launch after Aurobindo settles?

Potentially, but another company’s launch rights are governed by its own ANDA, certifications, litigation outcome, settlement and the patents still in force.

References

1. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd., No. 1:20-cv-01426, U.S. District Court for the District of Delaware, docket record.
4. Novartis Pharmaceuticals Corporation. (2024). Entresto prescribing information. U.S. Food and Drug Administration.